Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications.

Cardiovascular factors are one of the main causes of morbidity and mortality in patients with chronic kidney disease. Bone mineral metabolism disorders and inflammation are pathological conditions that involve increased cardiovascular risk in chronic kidney disease. The cardiovascular risk involvement of bone mineral metabolism classical biochemical parameters such as phosphorus, calcium, vitamin D and PTH is well known. The newest markers, FGF23 and klotho, could also be implicated in cardiovascular disease.

• Publication year

  2016

• Venue

  Nefrología

• Publication date

  2016-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.nefro.2016.01.011PMID 27118192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats

  2015cited by this paper
• Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.

  2015cited by this paper
• Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism.

  2014cited by this paper
• Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription.

  2014cited by this paper
• Fibroblast growth factor-23 and cardiovascular events in CKD.

  2014cited by this paper
• Evidence-based cardiology in hemodialysis patients.

  2013cited by this paper
• Arterial Klotho Expression and FGF23 Effects on Vascular Calcification and Function

  2013cited by this paper
• Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

  2013cited by this paper
• The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection

  2013cited by this paper
• Renal and extrarenal actions of Klotho.

  2013cited by this paper
• Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

  2013cited by this paper
• Mechanistic insights into vascular calcification in CKD.

  2013cited by this paper
• The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers

  2013cited by this paper
• Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

  2012cited by this paper
• Klotho as a potential biomarker and therapy for acute kidney injury

  2012cited by this paper
• Regulation and function of the FGF23/klotho endocrine pathways.

  2012cited by this paper
• Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet

  2012cited by this paper
• The emerging role of Klotho in clinical nephrology.

  2012cited by this paper
• Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

  2012cited by this paper
• UPDATE ON FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE

  2012cited by this paper
• 1,25-Dihydroxyvitamin D3 Regulation of Fibroblast Growth Factor-23 Expression in Bone Cells: Evidence for Primary and Secondary Mechanisms Modulated by Leptin and Interleukin-6

  2012cited by this paper
• IL-22 Signaling Contributes to West Nile Encephalitis Pathogenesis

  2012cited by this paper
• Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23

  2012cited by this paper
• A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model

  2012cited by this paper
• Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart

  2012cited by this paper
• Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone.

  2012cited by this paper
• Downregulation of NaPi-IIa and NaPi-IIb Na+-coupled Phosphate Transporters by Coexpression of Klotho

  2011cited by this paper
• FGF-23 as a predictor of renal outcome in diabetic nephropathy.

  2011cited by this paper
• Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-MM)

  2011cited by this paper
• CKD-mineral and bone disorder: core curriculum 2011.

  2011cited by this paper
• Klotho: an elixir of youth for the vasculature?

  2011cited by this paper
• Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

  2011cited by this paper
• PTH, FGF23, and calcium: it takes three to tango?

  2011cited by this paper
• Klotho deficiency causes vascular calcification in chronic kidney disease.

  2011cited by this paper
• Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.

  2011cited by this paper
• FGF23 induces left ventricular hypertrophy.

  2011cited by this paper
• Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease.

  2011cited by this paper
• Klotho Inhibits Transforming Growth Factor-β1 (TGF-β1) Signaling and Suppresses Renal Fibrosis and Cancer Metastasis in Mice*

  2011cited by this paper
• Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

  2011cited by this paper
• Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1α,25‐dihydroxyvitamin D3 synthesis in leptin‐deficient ob/ob Mice

  2010cited by this paper
• FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.

  2010cited by this paper
• FGF23 fails to inhibit uremic parathyroid glands.

  2010cited by this paper
• Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective.

  2010cited by this paper
• TRP-ing up Heart and Vessels: Canonical Transient Receptor Potential Channels and Cardiovascular Disease

  2010cited by this paper
• Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

  2010cited by this paper
• Regulation of Renal Outer Medullary Potassium Channel and Renal K+ Excretion by Klotho

  2009cited by this paper
• FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?

  2009cited by this paper
• High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

  2009cited by this paper
• Klotho is a target gene of PPAR-gamma.

  2008cited by this paper
• Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

  2007cited by this paper
• Prevalence of chronic kidney disease in the United States.

  2007cited by this paper
• Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice.

  2007cited by this paper
• Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23.

  2007cited by this paper
• Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.

  2007cited by this paper
• α-Klotho as a Regulator of Calcium Homeostasis

  2007cited by this paper
• Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells.

  2007cited by this paper
• The parathyroid is a target organ for FGF23 in rats.

  2007cited by this paper
• Regulation of Fibroblast Growth Factor-23 Signaling by Klotho*

  2006cited by this paper
• Klotho converts canonical FGF receptor into a specific receptor for FGF23

  2006cited by this paper
• Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

  2006cited by this paper
• TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.

  2006cited by this paper
• Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells.

  2006cited by this paper
• Riesgo cardiovascular en pacientes con enfermedad renal crónica

  2006cited by this paper
• An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

  2005cited by this paper
• Suppression of Aging in Mice by the Hormone Klotho

  2005cited by this paper
• Fibroblast growth factor 23: roles in health and disease.

  2005cited by this paper
• Oxidative Stress Decreases Klotho Expression in a Mouse Kidney Cell Line

  2005cited by this paper
• The ß-Glucuronidase Klotho Hydrolyzes and Activates the TRPV5 Channel

  2005cited by this paper
• Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients

  2005cited by this paper
• Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach

  2005cited by this paper
• The phosphatonin pathway: new insights in phosphate homeostasis.

  2004cited by this paper
• A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients.

  2004cited by this paper
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

  2004cited by this paper
• Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice.

  2004cited by this paper
• Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

  2004cited by this paper
• Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies.

  2004cited by this paper
• Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.

  2004cited by this paper
• FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.

  2003cited by this paper
• Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis

  2003cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

  2003cited by this paper
• Control of Cardiac Growth and Function by Calcineurin Signaling*

  2003cited by this paper
• Traditional and emerging cardiovascular risk factors in end-stage renal disease.

  2003cited by this paper
• Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.

  2002cited by this paper
• Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.

  2002cited by this paper
• Mediation of Unusually High Concentrations of 1,25-Dihydroxyvitamin D in Homozygous klotho Mutant Mice by Increased Expression of Renal 1α-Hydroxylase Gene.

  2002cited by this paper
• In Vivo klotho Gene Transfer Ameliorates Angiotensin II-Induced Renal Damage

  2002cited by this paper
• Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

  2002cited by this paper
• Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

  2001cited by this paper
• Phosphate regulation of vascular smooth muscle cell calcification.

  2000cited by this paper
• Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein.

  1998cited by this paper
• Mutation of the mouse klotho gene leads to a syndrome resembling ageing

  1997cited by this paper

• Specific associations of serum FGF23 and soluble Klotho with different types of left ventricular hypertrophy in hypertensive peritoneal dialysis patients: a cross-sectional study

  2026cites this paper
• Effects of Fibroblast Growth Factor 23 (FGF23) on the Cardiovascular System: A Review of Literature

  2025cites this paper
• Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health

  2022cites this paper
• In transfusion-dependent thalassemia children, increased iron overload is associated with lower serum alpha-klotho, which is strongly associated with lower total and ionized calcium concentrations.

  2022cites this paper
• Role of Vitamin K in CKD: Is Its Supplementation Advisable in CKD Patients?

  2021cites this paper
• Investigation on urinary and serum alpha klotho in dogs with chronic kidney disease

  2020cites this paper
• Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate)

  2019cites this paper
• Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins

  2019cites this paper
• The role of klotho in chronic kidney disease

  2018cites this paper
• The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio, Deemed the Nephron Index, Is a Useful Clinical Index for Early Stage Chronic Kidney Disease in Patients with Type 2 Diabetes: An Observational Pilot Study

  2018cites this paper
• Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases.

  2018cites this paper
• Potential application of klotho in human chronic kidney disease.

  2017cites this paper
• Role of pyrophosphate in vascular calcification in chronic kidney disease.

  2017cites this paper
• Decreased Level of Klotho Contributes to Drug Resistance in Lung Cancer Cells: Involving in Klotho-Mediated Cell Autophagy

  2016cites this paper